Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2020-04-17
Original SEC Filing: Click here

---

Webplus: SVA/20200417/6-K/2_EX-99.1/000.htm SEC Original: tm2016203d1_ex99-1.htm
Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING –(BUSINESS WIRE)– April 17, 2020– Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has commenced Phase I clinical trial, a randomized, double-blinded, placebo controlled study, for its vaccine candidate against COVID-19. Enrollment

---

---

Webplus: SVA/20200417/6-K/1/000.htm SEC Original: tm2016203d1_6k.htm

---

Company Info:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2020-04-17CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 15 ZHI TONG ROAD,, ZHONGGUANCUN TECH PARK, CHANGPING DISTR.
BEIJING 102200